GLP-1-based drugs are licensed for the treatment of obesity, yet they too produce a CTA response in rodents and activate the lateral PBN (Thiele et al., 1997). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.